Sera Prognostics (SERA) vs Exagen (XGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Exagen (XGN) has outperformed Sera Prognostics (SERA) over the past year, losing 25.6% versus a loss of 35.9%. Over five years, XGN leads with a -35.3% price change compared with -81.4% for SERA. Exagen is the larger company by market cap ($197.9 million vs $79.7 million), about 2.5 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SERA | XGN |
|---|---|---|
| Share price | $2.02 | $8.17 |
| Market cap | $79.69M | $197.92M |
| 1-day change | -2.42% | -1.57% |
| YTD return | -31.53% | +34.38% |
| 1-year return | -35.87% | -25.59% |
| 5-year return | -81.38% | -35.31% |
| EPS (TTM) | $-0.67 | $-0.81 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.95 | $12.23 |
| 52-week low | $1.56 | $2.59 |
| Distance from 52-week high | -48.86% | -33.20% |
| Analyst consensus | none | none |
| Avg. price target upside | +172.28% | +24.11% |
| Average volume | 28.38K | 328.42K |
| Shares outstanding | 38.48M | 24.23M |
| Employees | 71 | 216 |
| Sector | Health Care | Health Care |
| Industry | Medical Specialities | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Exagen is about 2.5 times larger than Sera Prognostics by market value ($197.92M vs $79.69M).
- XGN has outperformed SERA by 10.3 percentage points over the past year.
About Sera Prognostics
SERA stock →Sera Prognostics, Inc., a women's health company, discovers, develops, and commercializes blood-based biomarker tests, and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation.
Health Care · Medical Specialities · 71 employees
About Exagen
XGN stock →Exagen Inc. designs, develops, and commercializes various testing products under the AVISE brand in the United States.
Health Care · Medical Specialities · 216 employees
SERA vs XGN FAQ
Which is bigger, Sera Prognostics or Exagen?
Exagen (XGN) is larger, with a market capitalization of $197.92M compared with $79.69M for Sera Prognostics (SERA).
Which stock has performed better over the past year, SERA or XGN?
XGN returned -25.59% over the past 12 months, compared with -35.87% for SERA (price return, excluding dividends). Past performance does not predict future results.
Are Sera Prognostics and Exagen in the same industry?
Yes. Both are classified in the Medical Specialities industry within the Health Care sector.